Raltitrexed (Tomudex(TM)) in combination treatment for colorectal cancer: New perspectives

European Journal of Cancer

Volumn 35, Issue SUPPL. 1, 1999, Pages

  Van Cutsem, E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Combination therapy; Raltitrexed

Indexed keywords

ANTHRACYCLINE; CISPLATIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; THIOPHENES;

EID: 0033103493     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00040-4     Document Type: Conference Paper

References (21)

1. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322, 352-358.
3. Glimelius B., Hoffman K., Olafsdottir M., Pahlman L., Sjoden P.O., Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol. 25:1989;829-835.
4. Scheithauer W., Rosen H., Kornek G.V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306:1993;752-755.
5. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 1992, 10, 904-911.
6. O'Connell M.J., Laurie J.A., Kahn M.et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol. 16:1998;295-300.
7. Ardalan B., Luis R., Jaime M., Franceschi D. Biomodulation of fluorouracil in colorectal cancer. Cancer Invest. 16:1998;237-251.
8. Cunningham D. Mature results from three large controlled studies with raltitrexed (`Tomudex'). Br. J. Cancer. 77(Suppl. 2):1998;15-21.
9. Cocconi G., Cunningham D., Van Cutsem E.et al. Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J. Clin. Oncol. 16:1998;2943-2952.
10. Machover D., Diaz-Rubio E., de Gramont A.et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
11. De Gramont A., Eiger A., Seymour M.et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;A985.
12. Ratain MJ. New agents for colon cancer: Topoisomerase I inhibitors. In Perry MC, ed. American Society of Clinical Oncology Educational Book. 34th Annual meeting of the American Society of Clinical Oncology, California 1998, 311-315.
13. Cunningham D., Pyrhönen S., James R.D.et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
14. Rougier P., Van Cutsem E., Bajetta E.et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
15. Van Cutsem E., Pozzo C., Starkhammar H.et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann. Oncol. 9:1998;1199-1204.
16. Jackman AL, Mitchell F, Lynn S, et al. Evidence for the duration of the antifolate action of the thymidylate synthase (TS) inhibitor ZD9331 using plasma dUrd as a surrogate marker of enzyme inhibition. Ann Oncol 1998, 9(Suppl. 4), 125 (604O).
17. Teicher B.A., Ara G., Chen Y-N., Recht A., Coleman C.N. Interaction of Tomudex with radiation in vitro and in vivo. Int. J. Oncol. 13:1998;437-442.
18. Cvitkovic E. Ongoing and unsaid on oxaliplatin: The hope. Br. J. Cancer. 77(Suppl. 4):1998;8-11.
19. Valentini V., Ziccarelli L., Rosetto M.E., Marmiroli L., Coco C. Organ preservation in rectal cancer. Rays. 22:1997;454-459.
20. Mayer R.J., O'Connell M.J., Tepper J.E., Wolmark N. Status of adjuvant therapy for colorectal cancer. J. Natl. Cancer Inst. 81:1989;1359-1364.
21. American Cancer Society. Facts and Figures 1998. http://www.cancer.org/statistics/cff98/graphicaldata.html.